These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28008178)

  • 61. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
    Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
    Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Upregulation of PIM2 by Underexpression of MicroRNA-135-5p Improves Survival Rates of Skin Allografts by Suppressing Apoptosis of Fibroblast Cells.
    Zhang H
    Med Sci Monit; 2017 Jan; 23():107-113. PubMed ID: 28064305
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia.
    Kapelko-Slowik K; Owczarek TB; Grzymajlo K; Urbaniak-Kujda D; Jazwiec B; Slowik M; Kuliczkowski K; Ugorski M
    Leuk Lymphoma; 2016 Sep; 57(9):2140-9. PubMed ID: 26764044
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.
    Czudor Z; Balogh M; Bánhegyi P; Boros S; Breza N; Dobos J; Fábián M; Horváth Z; Illyés E; Markó P; Sipos A; Szántai-Kis C; Szokol B; Őrfi L
    Bioorg Med Chem Lett; 2018 Feb; 28(4):769-773. PubMed ID: 29329658
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The PIM kinases in hematological cancers.
    Alvarado Y; Giles FJ; Swords RT
    Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
    [TBL] [Abstract][Full Text] [Related]  

  • 67. pim-1 proto-oncogene expression in anti-CD3-mediated T cell activation is associated with protein kinase C activation and is independent of Raf-1.
    Wingett D; Long A; Kelleher D; Magnuson NS
    J Immunol; 1996 Jan; 156(2):549-57. PubMed ID: 8543805
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells.
    An N; Lin YW; Mahajan S; Kellner JN; Wang Y; Li Z; Kraft AS; Kang Y
    Stem Cells; 2013 Jun; 31(6):1202-12. PubMed ID: 23495171
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
    Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
    [TBL] [Abstract][Full Text] [Related]  

  • 70. NF-kappa B as a therapeutic target in multiple myeloma.
    Hideshima T; Chauhan D; Richardson P; Mitsiades C; Mitsiades N; Hayashi T; Munshi N; Dang L; Castro A; Palombella V; Adams J; Anderson KC
    J Biol Chem; 2002 May; 277(19):16639-47. PubMed ID: 11872748
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Combining chemical and genetic approaches for development of responsive FRET-based sensor systems for protein kinases.
    Manoharan GB; Enkvist E; Uri A
    Biophys Chem; 2016 Apr; 211():39-48. PubMed ID: 26874332
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Fructose-1, 6-bisphosphatase 1 interacts with NF-κB p65 to regulate breast tumorigenesis via PIM2 induced phosphorylation.
    Lu C; Ren C; Yang T; Sun Y; Qiao P; Han X; Yu Z
    Theranostics; 2020; 10(19):8606-8618. PubMed ID: 32754266
    [No Abstract]   [Full Text] [Related]  

  • 74. Long non-coding RNA SOX21-AS1 modulates lung cancer progress upon microRNA miR-24-3p/PIM2 axis.
    Wang F; Gu T; Chen Y; Chen Y; Xiong D; Zhu Y
    Bioengineered; 2021 Dec; 12(1):6724-6737. PubMed ID: 34511042
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
    Bullock AN; Russo S; Amos A; Pagano N; Bregman H; Debreczeni JE; Lee WH; von Delft F; Meggers E; Knapp S
    PLoS One; 2009 Oct; 4(10):e7112. PubMed ID: 19841674
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
    Agrawal S; Koschmieder S; Bäumer N; Reddy NG; Berdel WE; Müller-Tidow C; Serve H
    Leukemia; 2008 Jan; 22(1):78-86. PubMed ID: 17943165
    [TBL] [Abstract][Full Text] [Related]  

  • 78. PIM Kinase as an Executional Target in Cancer.
    Zhang X; Song M; Kundu JK; Lee MH; Liu ZZ
    J Cancer Prev; 2018 Sep; 23(3):109-116. PubMed ID: 30370255
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
    McMillin DW; Delmore J; Negri J; Ooi M; Klippel S; Miduturu CV; Gray NS; Richardson PG; Anderson KC; Kung AL; Mitsiades CS
    PLoS One; 2011; 6(7):e20226. PubMed ID: 21750699
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PIM2 interacts with tristetraprolin and promotes breast cancer tumorigenesis.
    Ren C; Yang T; Qiao P; Wang L; Han X; Lv S; Sun Y; Liu Z; Du Y; Yu Z
    Mol Oncol; 2018 May; 12(5):690-704. PubMed ID: 29570932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.